-
MU
Micron Technology
-
#1
-
AAPL
Apple
-
#2
-
NVDA
NVIDIA
-
#3
-
PLTR
Palantir Technologies
-
#4
-
SPCX
Space Exploration Technologies Corp.
-
#5
-
SNDK
Sandisk Corporation
-
#6
-
AVGO
Broadcom
-
#7
View the Zacks #1 Rank List
View All Zacks #1 Ranked Stocks
Zacks News
Wall Street Analysts Think Edgewise Therapeutics (EWTX) Could Surge 182%: Read This Before Placing a Bet
by Zacks Equity Research
The mean of analysts' price targets for Edgewise Therapeutics (EWTX) points to an 182% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Wall Street Analysts Believe Edgewise Therapeutics (EWTX) Could Rally 172.96%: Here's is How to Trade
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 173% in Edgewise Therapeutics (EWTX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
All You Need to Know About Edgewise Therapeutics (EWTX) Rating Upgrade to Buy
by Zacks Equity Research
Edgewise Therapeutics (EWTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Does Edgewise Therapeutics (EWTX) Have the Potential to Rally 174.68% as Wall Street Analysts Expect?
by Zacks Equity Research
The mean of analysts' price targets for Edgewise Therapeutics (EWTX) points to a 174.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
The Zacks Analyst Blog Highlights Pacira Biosciences, Edgewise, Sarepta Therapeutics, Amgen and Bristol Myers Squibb
by Zacks Equity Research
Pacira Biosciences, Edgewise, Sarepta Therapeutics, Amgen and Bristol Myers Squibb are included in this Analyst Blog.
Biotech Stock Roundup: PCRX Up on Patent News, EWTX Down on Study Data & More
by Ekta Bagri
PCRX and EWTX are in the spotlight this week following important regulatory and pipeline news.
EWTX Stock Down 48% in a Week Despite Upbeat Cardiomyopathy Study Data
by Zacks Equity Research
Edgewise Therapeutics stock plunges 48% in a week following safety concerns for its investigational hypertrophic cardiomyopathy treatment candidate, EDG-7500.
Biotech Stock Roundup: Updates From GILD, REGN, GSK, ANAB Down on Study Data, EWTX Gains
by Zacks Equity Research
GILD and GSK are in the spotlight in the biotech sector with quite a few regulatory and pipeline updates.
EWTX Stock Rises on Upbeat Data From Rare Muscular Disorder Study
by Zacks Equity Research
Data from a mid-stage study show that treatment with Edgewise's experimental drug reduces levels of a biomarker related to skeletal muscle damage.
Company News for Sep 20, 2024
by Zacks Equity Research
Companies In The News Are: PGNY, EWTX, FDS, SCS.